192 related articles for article (PubMed ID: 8114947)
1. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Hauber W; Andersen R
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
[TBL] [Abstract][Full Text] [Related]
2. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
Hauber W; Waldenmeier MT
Eur J Pharmacol; 1994 May; 256(3):339-42. PubMed ID: 7913894
[TBL] [Abstract][Full Text] [Related]
3. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.
Bubser M; Tzschentke T; Hauber W
J Neural Transm Gen Sect; 1995; 101(1-3):115-26. PubMed ID: 8695042
[TBL] [Abstract][Full Text] [Related]
4. Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist.
Tzschentke TM; Schmidt WJ
Eur J Pharmacol; 1996 Jan; 295(2-3):137-46. PubMed ID: 8720577
[TBL] [Abstract][Full Text] [Related]
5. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Zadow B; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
[TBL] [Abstract][Full Text] [Related]
6. Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice.
Lapin IP; Rogawski MA
Behav Brain Res; 1995 Oct; 70(2):145-51. PubMed ID: 8561905
[TBL] [Abstract][Full Text] [Related]
7. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Riedinger K; Kulak A; Schmidt WJ; von Ameln-Mayerhofer A
Behav Brain Res; 2011 Mar; 218(1):194-9. PubMed ID: 21130808
[TBL] [Abstract][Full Text] [Related]
8. Riluzole, a glutamate release inhibitor, and motor behavior.
Kretschmer BD; Kratzer U; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):181-90. PubMed ID: 9750003
[TBL] [Abstract][Full Text] [Related]
9. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
Moore NA; Blackman A; Awere S; Leander JD
Eur J Pharmacol; 1993 Jun; 237(1):1-7. PubMed ID: 8359205
[TBL] [Abstract][Full Text] [Related]
10. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
[TBL] [Abstract][Full Text] [Related]
11. Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism.
Bubser M; Zadow B; Kronthaler UO; Felsheim U; Rückert NG; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):767-73. PubMed ID: 9205962
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
Papa SM; Engber TM; Boldry RC; Chase TN
Eur J Pharmacol; 1993 Mar; 232(2-3):247-53. PubMed ID: 8385618
[TBL] [Abstract][Full Text] [Related]
13. The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists.
Hauber W; Münkle M
Naunyn Schmiedebergs Arch Pharmacol; 1996 Jul; 354(2):179-86. PubMed ID: 8857595
[TBL] [Abstract][Full Text] [Related]
14. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.
Kretschmer BD; Zadow B; Volz TL; Volz L; Schmidt WJ
J Neural Transm Gen Sect; 1992; 87(1):23-35. PubMed ID: 1346965
[TBL] [Abstract][Full Text] [Related]
15. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
Verma A; Kulkarni SK
Psychopharmacology (Berl); 1992; 109(4):477-83. PubMed ID: 1365866
[TBL] [Abstract][Full Text] [Related]
16. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization.
Tzschentke TM; Schmidt WJ
Behav Brain Res; 1997 Mar; 84(1-2):99-107. PubMed ID: 9079776
[TBL] [Abstract][Full Text] [Related]
17. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
McAllister KH
Eur J Pharmacol; 1996 Oct; 314(3):307-11. PubMed ID: 8957251
[TBL] [Abstract][Full Text] [Related]
18. Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
Melo LL; Santos P; Medeiros P; Mello RO; Ferrari EA; Brandão ML; Maisonnette SS; Francisco A; Coimbra NC
Brain Res; 2010 Aug; 1349():41-7. PubMed ID: 20558148
[TBL] [Abstract][Full Text] [Related]
19. [Glutamate receptor antagonists attenuate experimental catalepsy in rats].
Rukoiatkina NI; Gorbunova LV; Gmiro VE; Lukomskaia NIa
Ross Fiziol Zh Im I M Sechenova; 2000 Jun; 86(6):626-33. PubMed ID: 10955300
[TBL] [Abstract][Full Text] [Related]
20. Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
Sevak RJ; Koek W; France CP
Eur J Pharmacol; 2005 Jul; 517(1-2):64-7. PubMed ID: 15975572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
